Acer therapeutics receives $1 million capital infusion from chief executive officer and founder

Promissory note extends cash runway into early q3 2023 olpruva™ expected to be available by prescription in the u.s. beginning july 5 th newton, mass., june 26, 2023 (globe newswire) -- acer therapeutics inc. (nasdaq: acer ), a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious, rare and life-threatening diseases with significant unmet medical needs, today announced it has received $1,000,000 in funding in exchange for the issuance of an unsecured, subordinated promissory note for that principal amount to christopher schelling, the company's chief executive officer and founder, a member of the company's board of directors, and the beneficial owner of more than 10% of the company's outstanding common stock.
ACER Ratings Summary
ACER Quant Ranking